BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids — derived from a partial sequence of a protein found in human gastric juice. It is among the most widely studied peptides in preclinical literature and among the least studied in humans, a gap worth understanding before interpreting any result.
Structure and target
BPC-157 has no known dedicated receptor. That is unusual and it matters: rather than binding one target, its observed effects appear to be mediated through several existing signalling systems at once.
The best-characterised of these is angiogenic. In vitro work using human umbilical vein endothelial cells found that BPC-157 exposure increases phosphorylation of VEGFR2, the principal receptor for vascular endothelial growth factor, and drives its expression and internalisation. Downstream, this activates the VEGFR2–Akt–eNOS pathway along with MAPK/ERK signalling associated with endothelial proliferation and migration.
Additional pathways described in the literature include the FAK–paxillin axis, the nitric oxide system, growth hormone receptor expression in tendon fibroblasts, and effects along the gut–brain axis.
What the research has examined
Preclinical models have largely focused on tissue repair and cytoprotection. In rat Achilles tendon transection models, treated animals showed roughly a 2.3-fold increase in vascular density within the repair zone by day 14. Angiogenic activity has also been demonstrated in chick chorioallantoic membrane and endothelial tube-formation assays.
Gastrointestinal cytoprotection is the other major strand, unsurprising given the peptide was originally identified from a gastric protein.
The evidence gap, stated plainly
There are no published Phase III human clinical trials for BPC-157. Essentially all mechanistic data come from rats and mice, with supporting in vitro work in cell culture.
This is the single most important thing to understand about the compound. A large and consistent rodent literature is a reason to keep studying something. It is not evidence of a human effect, and the history of translational research is full of peptides that performed well in rodents and did nothing in people. Anyone presenting BPC-157 as an established human intervention is going beyond what the data supports.
Handling
Supplied lyophilised. Standard laboratory handling applies — see our reconstitution protocol for the technique that avoids degrading material during reconstitution, and store the dry cake cold and protected from light until use.
Every batch we supply ships with a third-party certificate of analysis. View BPC-157 10mg and its current COA.
Research use only
Isla Longevity supplies this compound for laboratory research use only. It is not approved by the FDA for human or veterinary use and is not for human consumption. This article summarises published research and is not medical guidance, nor a claim that this compound is safe or effective for any use in people.
